Cervical cancer: real-world data highlights value of HPV vaccine market
A recent study found that the UK’s HPV vaccine programme has dramatically reduced cervical cancer rates in the country.
Immunology
BCG: the history and modern-day uses of the tuberculosis vaccine
With the BCG jab showing promise against Covid-19, we profile the history of the TB...
4D Pharma Q&A: the potential of gut bacteria in cancer and beyond
4D Pharma CEO Duncan Peyton discusses the company’s work on bacteria-based therapies for cancer, neurodegeneration...
Syndax collaborates with Incyte to develop monoclonal antibody
The antibody will be developed to treat chronic graft-versus-host disease and other immune-mediated diseases.
AzurRx BioPharma to acquire First Wave Bio for $229m
AzurRx’s management team comprising CEO James Sapirstein will remain in the role to lead the...
Lilly collaborates with Lycia to develop new LYTAC degraders
The partnership plans to develop new degraders for up to five targets in Lilly’s focus areas, including immunology and pain.
BMS to in-license Exscientia’s AI-driven drug candidate
An option exercise fee of $20m will be paid to Exscientia by BMS, which will oversee the further development of the drug.
GentiBio raises $157m to develop Treg therapies for autoimmune diseases
The proceeds will be used to advance the company’s Treg therapy for type 1 diabetes into clinical trials.
Bayer to acquire Vividion for $1.5bn to boost drug discovery platform
Vividion will leverage Bayer’s experience, infrastructure and reach to autonomously develop its technology and portfolio.
ViiV Healthcare and Halozyme partner to develop long-acting HIV therapies
ViiV Healthcare and Halozyme plan to start experiments with ENHANZE by year-end for the drug cabotegravir for HIV prevention.
Umoja Biopharma raises $210m to advance next-gen cancer immunotherapy technology
The company is building an integrated cellular immunotherapy platform to reprogramme immune cells in vivo.
